Immunovant, Inc.
General ticker "IMVT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.2B (TTM average)
Immunovant, Inc. follows the US Stock Market performance with the rate: 59.2%.
Estimated limits based on current volatility of 2.4%: low 38.19$, high 40.10$
Factors to consider:
- Total employees count: 315 (-13.0%) as of 2026
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Market competition, Capital raising, Labor/talent shortage/retention
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-03-31 to 2028-03-30
- 2026-03-31 to 2027-03-31 estimated range: [16.46$, 39.03$]
- 2027-03-31 to 2028-03-30 estimated range: [13.19$, 32.37$]
Financial Metrics affecting the IMVT estimates:
- Negative: with PPE of -9.0 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Negative: Industry earnings per price (median), % of -12.99 <= 0
Short-term IMVT quotes
Long-term IMVT plot with estimates
Financial data
| YTD | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $27.51MM |
| Operating Expenses | $270.21MM | $438.15MM | $532.90MM |
| Operating Income | $-270.21MM | $-438.15MM | $-505.39MM |
| Non-Operating Income | $11.44MM | $25.20MM | $0.00MM |
| R&D Expense | $212.93MM | $360.92MM | $456.66MM |
| Income(Loss) | $-258.77MM | $-412.95MM | $-505.39MM |
| Taxes | $0.57MM | $0.89MM | $0.21MM |
| Net Income(Loss)* | $-259.34MM | $-413.84MM | $-505.61MM |
| Stockholders Equity | $617.76MM | $707.45MM | $852.59MM |
| Assets | $666.37MM | $776.22MM | $957.01MM |
| Operating Cash Flow | $-214.23MM | $-375.87MM | $-407.31MM |
| Capital expenditure | $0.36MM | $0.76MM | $0.01MM |
| Investing Cash Flow | $-0.36MM | $-0.76MM | $-0.01MM |
| Financing Cash Flow | $472.43MM | $454.49MM | $595.76MM |
| Earnings Per Share** | $-1.88 | $-2.73 | $-2.77 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.